Light therapy trial offers new hope for rare blood cancer patients

NCT ID NCT07075328

Recruiting now Disease control Sponsor: Otsuka Medical Devices Co., Ltd. Japan Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 15 times

Summary

This study tests a new treatment called OJP-001 for adults with a rare blood cancer (adult T-cell leukemia/lymphoma) that has come back after prior therapy. The treatment uses a light-activated drug and a machine to treat the blood outside the body. The goal is to find a safe dose and see if it can shrink tumors. About 49 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Imamura general hospital
RECRUITING

Kagoshima, Kagoshima-ken, Japan

Contact
Nagasaki University Hospital
RECRUITING

Nagasaki, Nagasaki, Japan

Contact
National Kyushu Cancer Center
RECRUITING

Fukuoka, Fukuoka, Japan

Contact
Sapporo Hokuyu Hospital
RECRUITING

Sapporo, Hokkaido, Japan

Contact
University of Miyazaki Hospital
RECRUITING

Miyazaki, Miyazaki, Japan

Contact

Conditions

Explore the condition pages connected to this study.

ADULT T-CELL LEUKEMIA/LYMPHOMA (ATLL) ADULT T-CELL LEUKEMIA/LYMPHOMA (ATLL)